SQUAREMIND raises €15.3 million to deploy Swan, its robotic dermatological imaging platform

SquareMind is accelerating its scale-up phase. The French startup, specialized in artificial intelligence and robotics applied to dermatology, has announced an $18 million funding round, approximately €15.3 million, to support the commercial launch of Swan™, its full-body skin imaging robot. The transaction comes amid increasing pressure on diagnostic capacity, where demand structurally exceeds available supply.

Screening is the most common act in dermatology, yet access delays can reach several months, or even up to a year in certain areas. This situation reflects broader demographic trends, particularly population ageing, while the need for longitudinal monitoring continues to rise. Comprehensive skin documentation is becoming a central issue, especially as 80% of melanomas appear as new lesions, requiring detection and comparison capabilities over time.

SquareMind is positioning itself precisely within this operational constraint. Its Swan™ platform combines robotics, high-resolution imaging, and artificial intelligence. The system enables full-body skin mapping in just a few minutes, with dermoscopic-level resolution comparable to magnified clinical examination. Image acquisition is automated and designed to integrate seamlessly into clinical workflows.

Beyond image capture, the platform aims to structure medical data. An AI-based assistance software facilitates image review and lesion tracking over time. The objective is to enhance the practitioner’s analytical capacity without replacing clinical decision-making. “Our technology acts as a companion: it helps reduce cognitive load, optimizes medical time, and enables comprehensive documentation, allowing physicians to focus on patient care and clinical decision-making,” explains Ali Khachlouf, co-founder and CEO of SquareMind.

The market in which the company operates remains in flux. It is structured around several categories of players, each addressing a different segment of the value chain. On the software side, companies such as SkinVision, Skin Analytics, and Legit.Health develop image analysis and triage solutions, often based on smartphone-captured photos. These approaches help democratize access to screening but remain dependent on the quality and heterogeneity of collected images.

At the other end of the spectrum, dermatological imaging manufacturers such as FotoFinder Systems and Heine Optotechnik provide equipment widely used in clinical practice. These systems enable highly precise analysis but are generally localized, focusing on specific lesions rather than full-body mapping.

Between these two approaches, a new generation of hybrid players is emerging, seeking to combine acquisition and analysis, although no dominant standard has yet been established. This fragmentation is particularly evident in the European market, where software innovation coexists with longstanding industrial expertise, without clear convergence toward an integrated model. In this environment—estimated at several billion euros and driven by sustained growth linked to the digitalization of care pathways—the ability to standardize data capture and analysis could become a key differentiating factor.

This is precisely where SquareMind aims to stand out. By integrating the entire value chain, automated acquisition, high-resolution imaging, and algorithmic analysis, the startup proposes a systemic approach to dermatological examination. The challenge extends beyond the tool itself: it is about building a longitudinal dataset capable of transforming monitoring and screening practices.

The announced funding is intended to industrialize this model. The company plans to strengthen its commercial, engineering, and customer support teams, with a view to simultaneous deployment in Europe and the United States, two markets characterized by significant pressure on access to dermatological care.

For investors, the value proposition lies as much in the technology as in its ability to integrate into medical practice. “Robotics and artificial intelligence will redefine medical practice by automating certain tasks, optimizing medical time while making excellence in care accessible to all. SquareMind has developed a platform that is unique in the world and is set to become a standard in modern dermatology,” says Kate Garrett, Managing Partner at Sonder Capital.

Founded in Paris, SquareMind develops dermatological imaging solutions combining artificial intelligence and robotics to improve the efficiency and accessibility of skin examinations. The company is led by Ali Khachlouf, co-founder and CEO. It has raised $18 million (approximately €15.3 million), including a previous pre-Series A round. The funding round is led by the Deep Tech 2030 fund, managed on behalf of the French state by Bpifrance as part of France 2030, and Sonder Capital, co-founded by Fred Moll. Adamed, Calm/Storm Ventures, Teampact Ventures, and several entrepreneurs also participated.